Posts

Lilly’s Foundayo Oral GLP-1 Prescriptions Cross 40,000

on

Eli Lilly’s “A Life Covered” campaign highlights lifelong obesity struggles and new Medicare GLP-1 access

on

Eli Lilly’s Foundayo builds scripts after a disappointing Q2 amid oral GLP‑1 race with Novo Nordisk’s Wegovy pill

on

Lilly’s obesity pill Foundayo slightly misses Q2 forecasts as injectables Mounjaro and Zepbound surge

on

Oral GLP-1 Tracker: Foundayo and Wegovy Pill Reach New Heights in Obesity Treatment Market

on

Current status: The Oral GLP-1 Tracker: Lilly takes time to build awareness for Foundayo as generic tirzepatide looms

on

With ADA 2026 data in the books, analysts say Lilly is widening its lead in the obesity race

on

Oral GLP‑1 Tracker: Novo’s oral Wegovy hits 3M prescription milestone as Lilly’s Foundayo chugs along in early launch

on

Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook

on

Lilly Highlights Low-Dose Zepbound and Foundayo for Long-Term Weight Loss Maintenance

on

Eli Lilly Invests Additional $4.5B in Indiana Manufacturing Facilities at LEAP District

on

Eli Lilly Touts Strong Early Launch of Foundayo Obesity Pill Despite Lagging Behind Novo's GLP-1

on

FDA Requests Additional Safety Data from Eli Lilly on Foundayo for Liver and Heart Risks

on

GoodRx Expands Access to Eli Lilly's New Oral GLP-1 Foundayo and Zepbound KwikPen with Self-Pay Pricing at Over 70,000 Pharmacies

on

Eli Lilly's Orforglipron Obesity Pill Gains FDA Approval, Challenging Novo Nordisk's Wegovy

on

FDA Approves Eli Lilly's Oral GLP-1 Pill Foundayo (Orforglipron) as Response to Novo Nordisk

on